Country: Armenja
Lingwa: Ingliż
Sors: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
fondaparinux (fondaparinux sodium)
Aspen Notre Dame de Bondeville
B01AX05
fondaparinux (fondaparinux sodium)
5mg/ml
solution for injection
(10) pre-filled syringes 0.5ml
Prescription
Registered
2015-07-31
ARIXTRA ™ Fondaparinux sodium (fondaparinux) QUALITATIVE AND QUANTITATIVE COMPOSITION Each syringe contains 2.5 mg of fondaparinux sodium in 0.5 ml solution for injection. The solution is a clear and colourless liquid. Each syringe contains 5.0 mg of fondaparinux sodium in 0.4 ml solution for injection. The solution is clear and colourless to slightly yellow. Each syringe contains 7.5 mg of fondaparinux sodium in 0.6 ml solution for injection. The solution is clear and colourless to slightly yellow. Each syringe contains 10.0 mg of fondaparinux sodium in 0.8 ml solution for injection. The solution is clear and colourless to slightly yellow. PHARMACEUTICAL FORM Injectable solution for subcutaneous and intravenous use. CLINICAL PARTICULARS Indications Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs such as: - hip fracture, including extended prophylaxis; - knee replacement surgery; - hip replacement surgery. Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are at risk of thromboembolic complications. Prevention of Venous Thromboembolic Events (VTE) in medical patients who are at risk of thromboembolic complications due to restricted mobility during acute illness. Treatment of acute Deep Vein Thrombosis (DVT). Treatment of acute Pulmonary Embolism (PE). Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) acute coronary syndrome for the prevention of death, myocardial infarction and refractory ischaemia. _ARIXTRA_ has been shown to reduce all cause mortality in patients with UA/NSTEMI. Treatment of ST segment elevation myocardial infarction (STEMI) acute coronary syndrome for the prevention of death and myocardial re-infarction in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy. _ARIXTRA_ has been shown to reduce all cause mortality in patients with STEMI. Dosage and Administration Method of administr Aqra d-dokument sħiħ
1 SUMMARY OF PRODUCT CHARACTERISTICS ARIXTRA™ FONDAPARINUX SODIUM (FONDAPARINUX) QUALITATIVE AND QUANTITATIVE COMPOSITION Each syringe contains 2.5 mg of fondaparinux sodium in 0.5 ml solution for injection. The solution is a clear and colourless liquid. Each syringe contains 5.0 mg of fondaparinux sodium in 0.4 ml solution for injection. The solution is clear and colourless to slightly yellow. Each syringe contains 7.5 mg of fondaparinux sodium in 0.6 ml solution for injection. The solution is clear and colourless to slightly yellow. Each syringe contains 10.0 mg of fondaparinux sodium in 0.8 ml solution for injection. The solution is clear and colourless to slightly yellow. PHARMACEUTICAL FORM Injectable solution for subcutaneous and intravenous use. CLINICAL PARTICULARS INDICATIONS Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs such as: - hip fracture, including extended prophylaxis; - knee replacement surgery; - hip replacement surgery. Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are at risk of thromboembolic complications. Prevention of Venous Thromboembolic Events (VTE) in medical patients who are at risk of thromboembolic complications due to restricted mobility during acute illness. Treatment of acute Deep Vein Thrombosis (DVT). Treatment of acute Pulmonary Embolism (PE). 2 Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) acute coronary syndrome for the prevention of death, myocardial infarction and refractory ischaemia. _ARIXTRA_ has been shown to reduce all cause mortality in patients with UA/NSTEMI. Treatment of ST segment elevation myocardial infarction (STEMI) acute coronary syndrome for the prevention of death and myocardial re-infarction in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy. _ARIXTRA_ has been shown to reduce all cause mortality in patients with STEMI. DOSAGE Aqra d-dokument sħiħ